Bioton reducing its lossesBioton, Poland’s largest insulin manufacturer, managed to reduce its net loss after nine months of the year to 5.9 million zlotys (1.4 million euros), compared with 12.7 million zlotys (3 million euros) in the corresponding period of 2016, reported Parkiet Gazeta Gieldy (p3) on Saturday.
Celon Pharma’s most important drug registered in PortugalSalmex, the most important drug in Celon Pharma’s portfolio used for treating asthma, has been registered in Portugal, reported Parkiet Gazeta Gieldy (p4) on Saturday.
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.